Skip to Content

Guardant Health Inc - Stock Quote GH

Rating as of

Morningstar's Guardant Health Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Guardant Reports Good Q1 Growth; Slightly Delayed Trial Read-Out Does not Change Our Long-Term View

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Coming amidst market volatility and a share price seemingly in free fall, Guardant Health reported solid first-quarter results with top-line growth meeting expectations, and a net loss coming in a tad lower than we had anticipated. Though our no-moat rating and $91 fair value estimate are unchanged, we continue to believe Guardant’s strengthening intangible assets supports the firm’s positive moat trend rating. We see shares as undervalued, with the stock trading at a price to fair value estimate ratio of 0.56.

Read Full Analysis

Guardant Health Inc's Company Profile

Business Description

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Contact
505 Penobscot Drive
Redwood City, CA, 94063
T +1 855 698-8887
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 1,373